Showing results (31-40 of 912) with videos related to
Sort By:
Pageof 92
F1000Research|May 10, 2019
RANKL is a therapeutic target of bone destruction in rheumatoid arthritisSakae TanakaClinical Calcium|March 19, 2005
[Therapeutic vaccination approach against pathological bone disease]Sakae TanakaNihon Rinsho. Japanese Journal of Clinical Medicine|September 16, 2006
[Bone disease related to rheumatoid arthritis]Sakae TanakaEFORT Open Reviews|May 7, 2019
Molecular understanding of pharmacological treatment of osteoporosisSakae TanakaClinical Calcium|April 4, 2007
[RANKL as a target molecule for treatment of joint destruction]Sakae TanakaAmerican Journal of Nephrology|July 27, 2007
Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG systemSakae TanakaNihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|February 13, 2019
[Hypoxia epigenetically bestows astrocytic differentiation potential on human pluripotent cell-derived neural stem/precursor cells]Tetsuro Yasui, Kinichi NakashimaJournal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 10, 2011
Regulation of RANKL-induced osteoclastogenesis by TGF-β through molecular interaction between Smad3 and Traf6Tetsuro Yasui, Yuho Kadono, Masaki Nakamura, et al.Bone Reports|April 6, 2017
Individual and combining effects of anti-RANKL monoclonal antibody and teriparatide in ovariectomized miceNaoto Tokuyama, Jun Hirose, Yasunori Omata, et al.Annals of the New York Academy of Sciences|April 16, 2010
Antiapoptotic molecule Bcl-2 is essential for the anabolic activity of parathyroid hormone in boneYuichi Nagase, Mitsuyasu Iwasawa, Toru Akiyama, et al.Pageof 92